Log in

NASDAQ:APTX - Aptinyx Stock Price, Forecast & News

$3.22
+0.09 (+2.88 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$3.03
Now: $3.22
$3.27
50-Day Range
$3.12
MA: $3.81
$5.03
52-Week Range
$2.61
Now: $3.22
$5.87
Volume151,726 shs
Average Volume399,186 shs
Market Capitalization$141.18 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APTX
CUSIPN/A
CIKN/A
Phone847-871-0377

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.57 million
Book Value$4.46 per share

Profitability

Net Income$-53,280,000.00
Net Margins-1,523.09%

Miscellaneous

EmployeesN/A
Market Cap$141.18 million
Next Earnings Date3/19/2020 (Estimated)
OptionableNot Optionable

Receive APTX News and Ratings via Email

Sign-up to receive the latest news and ratings for APTX and its competitors with MarketBeat's FREE daily newsletter.


Aptinyx (NASDAQ:APTX) Frequently Asked Questions

What is Aptinyx's stock symbol?

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

How were Aptinyx's earnings last quarter?

Aptinyx Inc (NASDAQ:APTX) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.44) EPS for the quarter, hitting analysts' consensus estimates of ($0.44). The company earned $0.94 million during the quarter, compared to analysts' expectations of $0.91 million. Aptinyx had a negative return on equity of 44.24% and a negative net margin of 1,523.09%. View Aptinyx's Earnings History.

When is Aptinyx's next earnings date?

Aptinyx is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Aptinyx.

What price target have analysts set for APTX?

6 brokerages have issued 1-year price objectives for Aptinyx's shares. Their forecasts range from $7.00 to $12.00. On average, they anticipate Aptinyx's stock price to reach $10.33 in the next year. This suggests a possible upside of 220.9% from the stock's current price. View Analyst Price Targets for Aptinyx.

What is the consensus analysts' recommendation for Aptinyx?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptinyx.

Has Aptinyx been receiving favorable news coverage?

News coverage about APTX stock has been trending extremely negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aptinyx earned a daily sentiment score of -4.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Aptinyx.

Are investors shorting Aptinyx?

Aptinyx saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 192,200 shares, an increase of 13.4% from the January 15th total of 169,500 shares. Based on an average trading volume of 240,200 shares, the short-interest ratio is currently 0.8 days. Currently, 0.9% of the company's stock are short sold. View Aptinyx's Current Options Chain.

Who are some of Aptinyx's key competitors?

What other stocks do shareholders of Aptinyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), ADMA Biologics (ADMA), Canopy Growth (CGC), Kadmon (KDMN), Inovio Pharmaceuticals (INO), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX).

Who are Aptinyx's key executives?

Aptinyx's management team includes the folowing people:
  • Dr. Norbert G. Riedel, Pres, CEO & Director (Age 61)
  • Dr. Joseph R. Moskal Ph.D., Chief Scientific Officer (Age 68)
  • Dr. Torsten Meldgaard Madsen, Chief Medical Officer (Age 51)
  • Mr. Ashish Khanna, CFO & Chief Bus. Officer (Age 43)
  • Ms. Betty Y. Jang, VP of Legal Affairs (Age 50)

When did Aptinyx IPO?

(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Who are Aptinyx's major shareholders?

Aptinyx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Farallon Capital Management LLC (0.93%), Renaissance Technologies LLC (0.70%), Jacobs Levy Equity Management Inc. (0.43%), Oxford Asset Management LLP (0.40%), Marshall Wace LLP (0.33%) and Acadian Asset Management LLC (0.26%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View Institutional Ownership Trends for Aptinyx.

Which institutional investors are selling Aptinyx stock?

APTX stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Marshall Wace LLP, Oxford Asset Management LLP, Russell Investments Group Ltd., Alambic Investment Management L.P. and Goldman Sachs Group Inc.. View Insider Buying and Selling for Aptinyx.

Which institutional investors are buying Aptinyx stock?

APTX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., DCF Advisers LLC, Spark Investment Management LLC and Acadian Asset Management LLC. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View Insider Buying and Selling for Aptinyx.

How do I buy shares of Aptinyx?

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aptinyx's stock price today?

One share of APTX stock can currently be purchased for approximately $3.22.

How big of a company is Aptinyx?

Aptinyx has a market capitalization of $141.18 million and generates $6.57 million in revenue each year. The company earns $-53,280,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. View Additional Information About Aptinyx.

What is Aptinyx's official website?

The official website for Aptinyx is http://www.aptinyx.com/.

How can I contact Aptinyx?

Aptinyx's mailing address is 1801 MAPLE AVENUE SUITE 4300, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]


MarketBeat Community Rating for Aptinyx (NASDAQ APTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  190
MarketBeat's community ratings are surveys of what our community members think about Aptinyx and other stocks. Vote "Outperform" if you believe APTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel